Vaccines
30 September 2013
MOLOGEN AG: Final analysis confirmed preliminary results of renal cancer vaccine MGN160126 September 2013
Takeda Submits New Drug Application in Japan for TAK-816, a Haemophilus Influenzae type b (Hib) vaccine26 September 2013
NovaDigm Therapeutics Initiates Phase 1b/2a Clinical Trial with NDV-3 Vaccine in Recurrent Vulvovaginal Candidiasis (RVVC)25 September 2013
Merck Serono Announces Decision to Continue the Development of Tecemotide in Stage III Non-Small Cell Lung Cancer20 September 2013
Fluenz Tetra, four-strain nasal spray vaccine, receives positive opinion in EU from CHMP for the prevention of seasonal influenza in children18 September 2013
Top-Line Analysis of CVac(TM) Phase 2 Trial; Ovarian Cancer Clinical Development Update17 September 2013
Profectus BioSciences Announces Initiation of Clinical Trial Evaluating its Therapeutic HIV Vaccine in Support of the “Cure Agenda”17 September 2013
Agenus Reports Positive Follow-on Phase 2 Results for Brain Cancer Vaccine in Newly Diagnosed Patients16 September 2013
ISA Pharmaceuticals Initiates Phase I/II Clinical Trial of ISA101 in Patients with Anal Intraepithelial Neoplasia (AIN)12 September 2013
Circassia’s Short-Course House Dust Mite Allergy Treatment Achieves Significant Long-Term Symptom Reduction11 September 2013
ICAAC Presentations Highlight Potential Protective Effects of Novavax’ RSV Vaccine Candidate10 September 2013
Roche and Inovio Pharmaceuticals partner on Inovio’s prostate cancer and hepatitis B immunotherapy products9 September 2013
Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma9 September 2013
Immunovaccine Reports Positive Results from Two Anthrax Studies6 September 2013
PaxVax Initiates Phase 3 Clinical Trial Challenge Studies for Single-Dose Oral Cholera Vaccine5 September 2013
GSK’s MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Melanoma Misses First Co-Primary Endpoint5 September 2013
Apitope Announces Positive Results from Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis4 September 2013
Transgene Announces that its Phase 2 study of Pexa-Vec in Second-line Advanced Liver Cancer did not Meet its Primary Endpoint4 September 2013
Imaxio announces the first human clinical trial using its pro-immunogenic technology IMX313 in tuberculosis4 September 2013
Publication Demonstrates Superior Activity of ISA Pharmaceuticals´ SLP® Vaccines Compared to Whole Protein VaccinesNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports